We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Protein Biomarker Testing Services and Products Offered in China

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Protein Biomarker Testing Services and Products Offered in China"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

LightArray operates a comprehensive drug development services laboratory in Wuxi, China and will now provide researchers with a local, centralized protein biomarker testing laboratory employing Aushon’s protein biomarker technologies including:

•    A growing menu of 300+ validated assays
•    Multiplex biomarker sample testing service
•    Multiplex protein biomarker kits
•    Custom arrays and assay development
•    Array imaging and analysis systems

 “Our strategic partnership with LightArray enables companies located in China and involved in pre-clinical and clinical research to take advantage of our full range of biomarker products and services, including our flexible sample testing service and growing menu of more than 300 biomarkers in key therapeutic areas such as oncology, inflammation, cardiovascular disease, and diabetes,” said Pete Honkanen, CEO of Aushon. “They can also count on the same exacting level of reliability, performance and support that we deliver to our current customers in the United States, Europe and Southeast Asia.”  

“We are extremely excited by the opportunity to assist Aushon in bringing their portfolio of multiplex biomarker services and products into the emerging China market,” said Alan Zhang, President and CEO of LightArray. “The adoption of biomarkers as a critical research tool in pre-clinical and clinical studies is growing rapidly in China, and our ability to provide local, regional access to the proven Aushon multiplex technology platform will be vital. We also look forward to providing the same unrivaled service and support to our customers that Aushon has built its reputation on.”